mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients.

Background: Splicing factor 3b subunit 1 (), a splicing factor modulating RNA alternative splicing, is frequently mutated in multiple hematological malignancies including myelodysplastic syndromes and chronic lymphocytic leukemia (CLL). The clinical impact of mutation on CLL remains controversial especially for patients of Asian descent.

Methods: We retrospectively analyzed the frequency of mutation by Sanger sequencing in 399 newly diagnosed Chinese CLL patients.

Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use.

We have developed a therapeutic approach to wound repair involving immobilization of gene transfer vectors within biocompatible matrices (gene-activated matrix, or GAM). The matrix also serves as a scaffold for cellular in-growth and subsequent gene uptake and expression. An adenoviral vector encoding human platelet-derived growth factor-B delivered in collagen (AdPDGF-B/GAM) has demonstrated efficacy in models of wound repair.